Tetra Bio-Pharma hopes $6M raise carries firm through to revenue stage
Orléans-based company has spent years developing drugs designed to mimic the pain-killing and anti-inflammatory benefits of cannabis without major side effects.
Tetra Bio-Pharma hopes $6M raise carries firm through to revenue stage
Orléans-based company has spent years developing drugs designed to mimic the pain-killing and anti-inflammatory benefits of cannabis without major side effects.
Tetra Bio-Pharma closes $10M public offering to fund drug research
CEO Guy Chamberland told OBJ earlier this year firm is working on breakthrough treatments for sepsis and acute respiratory distress syndrome.
Ottawa drug-maker Tetra Bio-Pharma’s decade-long research effort may be poised to pay off
Product is designed to treat life-threatening conditions triggered when the body’s immune system “goes rogue” in response to infections such as COVID-19.
Ottawa’s Tetra Bio-Pharma graduates to TSX
Bioscience firm that’s developing cannabinoid-based treatments for chronic pain is slated to move up from TSX Venture Exchange on Aug. 4.
Ottawa’s Tetra Bio-Pharma closes $9.2M public offering
Funds will be used to advance the company’s work on QIXLEEF, a therapy to treat uncontrolled pain in advanced cancer patients that’s in the late-phase
Ottawa-based Tetra Bio-Pharma to raise $10M
An Ottawa bioscience company is turning to the markets for an injection of capital, announcing plans this week for a bought deal offering
Shareholders approve Ottawa-based Tetra Bio-Pharma’s $12M acquisition
Tetra Bio-Pharma’s shareholders are endorsing the local firm’s plans to accelerate its cannabidiol research efforts as excitement around the market for hemp-based products heats up.
Orléans-based Tetra Bio-Pharma acquires cannabinoid research firm in $12M deal
An east-end Ottawa research firm has acquired another pharmaceutical company working in the cannabinoid space, bolstering both its product pipeline and roster of researchers. Tetra
Ottawa’s Tetra Bio-Pharma to raise another $4.5M for cannabis therapies
Tetra Bio-Pharma (TSX-V:TBP) has announced plans to raise another $4.5 million in the coming weeks, just days after it closed another multimillion-dollar round earlier this
With Europe in sight, Ottawa’s Tetra Bio-Pharma closes $11.5M funding round
Tetra Bio-Pharma raised a few extra million dollars this week, as the Orléans-based firm announced an expansion into the European medical cannabis market. The local
Get up-to-date news about the companies, people and issues that impact businesses in Ottawa and beyond.
Sponsored
No poach clauses: Protect your workforce
Understanding search and seizure laws
Expanding Your business in the USA today?